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LETTER TO THE EDITOR
Survival rate in acute kidney injury superimposed COVID-19 patients: a
systematic review and meta-analysis
Dear Editor,
Of no doubt, the whole world is passing through a poten-
tially life-threatening and economically destructive global
pandemic caused by the novel coronavirus (COVID-19;
SARS-CoV-2; previously known as 2019-nCoV) [1]. The clin-
ical course of infection is widely unpredicted and variable,
ranging from asymptomatic infection to multi-organ sys-
tem failure and death [2–4]. Nevertheless, the survival rate
among patients with COVID-19 and superimposed acute
kidney injury (AKI) remains unclear [5,6]. Hence; we ush-
ered a systemic review and meta-analysis exploring the
survival outcome of COVID-19 subjects who developed
severe AKI, the latter defined as subjects who require
acute renal replacement therapy (RRT) or meet the Kidney
Disease Improving Global Outcome (KDIGO) definition of
AKI stage III. We included all studies performed on human
beings for which baseline creatinine, occurrence of AKI
stage III and/or need for acute RRT were reported and
excluded case reports, review articles, or studies assessing
clinical characteristics and conference abstracts. Ethical
approval was not required for this work due to use of
anonymous data that is publicly available. A systematic
review in Pubmed, Medline, Embase and Cochrane data-
bases to select studies that met the inclusion criteria was
performed by 3 authors (H.A, M.M, A.A). The search terms
used were (coronavirus, COVID-19, SARS-COV-2 and (mor-
tality, survival, outcomes, dialysis, acute renal failure, acute
kidney injury, renal replacement therapy). These search
terms were individually used and then combined in differ-
ent databases. References within the chosen studies were
reviewed. All the included studies were reviewed by super-
vising authors. Any disagreement among authors collect-
ing the data was investigated by supervising authors.
Consensus among all authors was essential to include the
studies in the systematic review. The following data were
collected: name of the first author, journal title, publication
date, place of the study, sample size, baseline creatinine,
relative risk and confidence intervals for association of
acute renal failure and mortality. We followed the recom-
mendations of Cochrane collaboration and the Quality of
Reporting of Meta-analyses guidelines [7,8]. STATA pack-
age-15 was used for statistical analysis. We combined all
study-specific estimates using inverse-variant weighted
averages of logarithmic relative risk in random effects
model (REM). Confidence interval including the value of
one was used evident for statistically significant estimate.
Heterogeneity was evaluated using Higgins I-squared stat-
istic. Heterogeneity was estimated when the level of p
value was <.1. Results of the REM were spread out on the
forest plot graph. The Newcastle-Ottawa score was used to
evaluate the quality of the papers included. Egger’s test
was used to assess publication bias. A total of 2290
abstracts were reviewed. Out of six studies included in the
systematic review, only three studies met the inclusion cri-
teria and were pooled into a meta-analysis (PRISMA dia-
gram, Figure 1). Due to lack of a controlled survival group
(only severe AKI subjects were included), the studies by
Zhang et al. and Shi et al. were not included in the meta-
analysis [9,10]. As compared to Ruan et al., Cheng et al.’s
study was more recent, included a larger sample size and
since both shared the same cohort, only the latter was
included in our meta-analysis [5,11]. The baseline charac-
teristics of the studies included are shown in Table 1. The
Newcastle-Ottawa score of the included studies is shown
in Table 2. REM showed that severe AKI is associated with
higher risk of mortality (relative risk ¼ 3.08, confidence
interval ranges from 1.54 to 6.19) as shown in Figure 2.
There was evidence of heterogeneity with I-squared ¼90%
and p< .001. Publication bias was shown in the funnel
plot analysis in Figure 3. By applying Egger’s test for
assessment of bias, there was evidence of small studies
effect with p¼ .93.
To decrease risk of heterogeneity, REM was repeated
after excluding Yang et al (Figure 4). The association of
severe AKI with mortality persisted (relative risk ¼ 4.19,
95% CI 3.31 - 5.31). There was no evidence of heterogen-
eity with I-squared ¼ 0%, p¼ .68. There was no evidence
of publication bias when applying Eggers test (p< .05) or
funnel plot analysis (Figure 5). Our meta-analysis supports
that mortality is significantly higher in patients with severe
AKI in patients with COVID-19. To date, the published inci-
dence of AKI among patients with COVID-19 is highly vari-
able. It has been reported to occur in up to 27% of
patients with COVID-19 [12]. Our meta-analysis included
three studies addressing mortality in COVID-19 patients
with superimposed AKI. Cheng et al., included 701 COVID-
19 confirmed cases. AKI stage III occurred among 14/701
(2%) of the patients and was associated with an increased
risk of in-hospital mortality (hazard ratio ¼ 9.81, 95%
CI:5.46-17.65) [5]. Similarly, Yang et al. included 52 COVID-
19 confirmed cases in their study and found that 8 out of
9 subjects who required RRT did not survive [13]. Mirroring
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Yang et al.’s results, Zhou et al., in a study that included
191 COVID-19-CC, 10 out of 10 subjects who required RRT
did not survive [14]. In addition, the investigators reported
that out of 33 confirmed COVID-19 cases who developed
AKI, 32 patients did not survive [14]. The high mortality in
COVID-19 patients and severe AKI, even with RRT, could
Figure 1. PRISMA diagram for the systematic review.
Table 1. Baseline characteristics of studies included in the systematic review.
Name Journal
Date of
Publication Name of hospital
Study
population
Baseline creatinine Mean
(standard deviation)
Yang et al. Lancet Respiratory
Medicine
March 2020 Intensive care unit (ICU) of Wuhan Jin
Yin-tan hospital (Wuhan, China)
52 patients 76・3 (27・4) umol/L in
survivors80・7 (32・3) umol/
L in non-survivors
Cheng et al. Kidney International March 2020 Tongji Hospital, Wuhan, China 701 patients 77 ( 31) umol/L
Zhou et al. Lancet March 2020 Jinyintan Hospital and Wuhan
Pulmonary Hospital-China
191 patients 8 patients had baseline
creatinine >133umol/L
Zhang et al. medRxiv March 2020 Eastern Campus, Renmin Hospital,
Wuhan University, China
82 patients 78 umol/L
Ruan et al. Intensive care
medicine
March 2020 Jin Yin-tan Hospital and Tongji
Hospital,
150 patients 91 in non-survivors 72 in
survivors
Shi et al. medRxiv March 2020 Department of General Surgery,
Renmin Hospital of Wuhan
University,
101 patients 139.8 ± 22.83 umol/L
Table 2. Newcastle-Ottawa score of the included studies.
Study ID
Exposed cohort
representative
Non exposed
cohort selected
from same source
Exposure
ascertained
Outcome of study
was not present
at start of the study Comparability
Adequate
assessment
Follow up
was long
nough
Adequate
follow-up
Quality
score
Yang et al. yes Yes yes yes 1 yes yes yes 8
Cheng et al. yes Yes yes yes 1 yes yes yes 8
Zhou et al. yes Yes yes yes 1 yes yes yes 8
Zhang et al. yes No yes yes 0 yes yes yes 5
Ruan et al. Yes Yes Yes Yes 1 Yes Yes yes 8
Shi et al. yes No yes yes 0 yes yes no 5
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be due to the kidney-lung crosstalk during COVID-19 infec-
tion and amplification of inflammation during AKI in a
cohort with high incidence of acute respiratory distress
syndrome [15]. Based on the available limited published
data, severe AKI in patients with COVID-19 is an ominous
clinical predictor and is associated with high mortality.
Further studies are needed to understand the factors asso-
ciated with worse outcomes among COVID-19 patients
with AKI. Understanding those factors may guide care pro-
viders in making more informed dialysis eligibility deci-
sions under conditions where resources are extremely
limited.
Figure 2. Forest plot analysis.
Figure 3. Funnel plot.
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